PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta(®)): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers

INTRODUCTION: PF-06881894 is a proposed biosimilar to pegfilgrastim (Neulasta(®)). This study evaluated the pharmacodynamic/pharmacokinetic (PD/PK) equivalence, immunogenicity, and safety of PF-06881894 vs pegfilgrastim reference products (US- and EU-Neulasta(®)) in healthy volunteers. METHODS: A ph...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Adv Ther
Prif Awduron: Moosavi, Shahrzad, Borema, Troy, Ewesuedo, Reginald, Harris, Stuart, Levy, Jeffrey, May, Thomas B., Summers, Martin, Thomas, Jeffrey S., Zhang, Jeffrey, Yao, Hsuan-Ming
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Healthcare 2020
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7467414/
https://ncbi.nlm.nih.gov/pubmed/32524499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01387-x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg